Ellevest Inc. cut its holdings in shares of GSK plc (NYSE:GSK – Free Report) by 27.8% during the fourth quarter, HoldingsChannel.com reports. The fund owned 13,798 shares of the pharmaceutical company’s stock after selling 5,301 shares during the quarter. Ellevest Inc.’s holdings in GSK were worth $467,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Indiana Trust & Investment Management Co increased its stake in GSK by 200.0% in the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock valued at $25,000 after purchasing an additional 500 shares during the period. Crews Bank & Trust acquired a new position in GSK in the 4th quarter valued at about $26,000. ST Germain D J Co. Inc. lifted its position in GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 522 shares during the period. Sierra Ocean LLC purchased a new position in shares of GSK in the 4th quarter valued at approximately $32,000. Finally, Parkside Financial Bank & Trust raised its stake in shares of GSK by 470.1% during the fourth quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company’s stock worth $34,000 after purchasing an additional 818 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.
GSK Stock Down 0.7 %
GSK opened at $36.63 on Friday. The firm has a market cap of $75.58 billion, a P/E ratio of 23.04, a PEG ratio of 1.12 and a beta of 0.51. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The business’s fifty day simple moving average is $37.65 and its 200 day simple moving average is $36.00. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.93.
GSK Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be issued a $0.4216 dividend. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.60%. This is an increase from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, May 16th. GSK’s dividend payout ratio (DPR) is 86.60%.
Analyst Upgrades and Downgrades
A number of equities analysts recently weighed in on GSK shares. BNP Paribas started coverage on shares of GSK in a research report on Tuesday, April 15th. They issued a “neutral” rating and a $35.25 price objective on the stock. Morgan Stanley started coverage on shares of GSK in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. Hsbc Global Res raised GSK to a “strong sell” rating in a report on Monday, April 28th. Finally, StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research note on Thursday, April 24th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $40.58.
Read Our Latest Analysis on GSK
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Featured Stories
- Five stocks we like better than GSK
- Most Volatile Stocks, What Investors Need to Know
- Google Is Betting Big on Nuclear Reactors—Should You?
- Basic Materials Stocks Investing
- Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs
- Roth IRA Calculator: Calculate Your Potential Returns
- Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSK – Free Report).
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.